Eisai Archives -

danie-franco-unsplash-old-hands-dementia

News/ News/ Patients

Eisai steps up beyond-the-pill approach to dementia in Japan

Phil Taylor beyond the pill, dementia, Eisai, health insurance, Japan, Lifenet, patients 0 Comment

More and more pharma companies are looking “beyond the pill” when it comes to providing care for patients,

Eisai steps up beyond-the-pill approach to dementia in Japan

https://pharmaphorum.com/news/eisai-steps-up-beyond-the-pill-approach-to-dementia-in-japan/

Market Access/ News/ News

Eisai/Biogen could get FDA verdict on new Alzheimer’s drug by 6 Jan

Phil Taylor Aduhelm, Alzheimer's disease, Biogen, Eisai, fda, lecanemab, neurology, regulatory 0 Comment

The FDA has started an accelerated review of Eisai and Biogen’s a new amyloid-targeting antibody lecanemab for Alzheimer’s

Eisai/Biogen could get FDA verdict on new Alzheimer’s drug by 6 Jan

https://pharmaphorum.com/news/eisai-biogen-could-get-fda-verdict-on-new-alzheimers-drug-by-6-jan/

Digital/ News/ News

Eisai’s brain health tool NouKNOW used in Tokyo dementia project

Phil Taylor app, dementia, digital, digital health, Eisai, smartphones 0 Comment

Eisai’s digital tool to allow self-assessment of cognitive performance – NouKNOW – will be used in a Japanese

Eisai’s brain health tool NouKNOW used in Tokyo dementia project

https://pharmaphorum.com/news/eisais-brain-health-tool-nouknow-used-in-tokyo-dementia-project/

News/ News/ Oncology

ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC

Phil Taylor antibody-drug conjugate, Bristol-Myers Squibb, Eisai, immunogen, Oncology, ovarian cancer 0 Comment

Eisai’s first-ever attempt at developing an antibody-drug conjugate for cancer was rewarded with a $3.1 billion licensing deal

ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC

https://pharmaphorum.com/news/asco22-new-data-backs-bms-investment-in-eisais-first-cancer-adc/

Market Access/ News/ News

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go

Phil Taylor Aduhelm, Alzheimer's disease, amyloid, Biogen, Eisai, lecanemab, regulatory 0 Comment

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go

https://pharmaphorum.com/news/exit-aduhelm-enter-lecanemab-biogen-and-eisai-have-another-go/

Market Access/ News/ News/ News/ Sales and Marketing

Idorsia is first to EU market with orexin insomnia drug

Phil Taylor Belsomra, Dayvigo, Eisai, EU, Idorsia, insomnia, Quviviq, regulatory approval 0 Comment

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia

Idorsia is first to EU market with orexin insomnia drug

https://pharmaphorum.com/news/idorsia-is-first-to-eu-market-with-orexin-insomnia-drug/

Digital/ News/ News

Pharma group seeks digital measure standards for Alzheimer’s

Phil Taylor Alzheimer's disease, Biogen, digital, digital health, Digital Medicine Society (DiMe), Eisai, Eli Lilly, Merck & Co 0 Comment

A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to

Pharma group seeks digital measure standards for Alzheimer’s

https://pharmaphorum.com/news/pharma-group-seeks-digital-measure-standards-for-alzheimers/

News/ News/ Sales and Marketing

Eisai hands off responsibility for Aduhelm to Biogen

Phil Taylor Aduhelm, Alzheimer's disease, Biogen, Eisai, Financial, neurology 0 Comment

Japanese pharma Eisai has backed away from its 50:50 profit-sharing arrangement with Biogen for troubled Alzheimer’s therapy Aduhelm,

Eisai hands off responsibility for Aduhelm to Biogen

https://pharmaphorum.com/news/eisai-hands-off-responsibility-for-aduhelm-to-biogen/

News/ News/ R&D

Roche starts new four-year trial of Alzheimer’s drug gantenerumab

Phil Taylor Alzheimer's disease, Biogen, donanemab, Eisai, Eli Lilly, gantenerumab, lecanemab, neurology, Roche 0 Comment

With prospects of an early, accelerated approval for Roche’s Alzheimer’s disease candidate gantenerumab looking diminished, the drugmaker has

Roche starts new four-year trial of Alzheimer’s drug gantenerumab

https://pharmaphorum.com/news/roche-starts-new-four-year-trial-of-alzheimers-drug-gantenerumab/

Trending

Eisai

Login